An Open Label Compassionate Use Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials With B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Trial Profile

An Open Label Compassionate Use Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials With B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2018

At a glance

  • Drugs Ublituximab (Primary) ; Umbralisib (Primary)
  • Indications Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Expanded access
  • Sponsors TG Therapeutics Inc
  • Most Recent Events

    • 07 Aug 2018 According to TG Therapeutics Inc media release, data from the trial presented at the 54th Annual Meeting of the American Society of Clinical Oncology and at the 23rd Congress of the EHA.
    • 01 Jun 2018 According to TG Therapeutics Inc media release, data from this trial will be presented at the 54th Annual Meeting of the American Society of Clinical Oncology and the 23rd Congress of the European Hematology Association.
    • 04 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top